海尔生物营收超23亿元，AI贡献营收占比达15%

Core Viewpoint - Haier Biomedical's performance report indicates a revenue of 2.33 billion yuan for 2025, reflecting a year-on-year growth of 2.0%, with overseas revenue reaching 840 million yuan, accounting for 36% of total revenue. The company continues to innovate and deepen its global layout, leading to improved profitability [1][2]. Group 1: Revenue and Growth - In 2025, Haier Biomedical achieved a revenue of 2.33 billion yuan, marking a 2.0% increase year-on-year, with a fourth-quarter revenue growth of 13.1% [2]. - The overseas revenue reached 840 million yuan, showing a year-on-year growth of 17.9%, and its share of total revenue increased by 5 percentage points compared to 2024 [3]. - The new industries and markets, along with AI engines, are driving strong growth momentum for the company [2]. Group 2: Product Performance and Market Position - Haier Biomedical's products have gained widespread trust globally, with its ultra-low temperature and constant temperature product lines leading the market in six countries [4]. - The company has implemented a localized strategy, with operational teams covering 18 countries and over 400 local product certifications [5]. - New industries contributed significantly to revenue, with new industry revenue accounting for 48.5% of total revenue, growing by 8.8% year-on-year [6]. Group 3: Innovations and Technological Advancements - The smart medication industry showed remarkable growth of 18.8%, with the company ranking among the top three in market share for automated medication [6]. - The blood technology sector also maintained double-digit growth at 14.8%, with a market share exceeding 50% in plasma collection solutions [7]. - AI technology has become a significant driver of revenue, contributing 15% to total revenue in 2025, an increase of 2.5 percentage points from 2024 [10]. Group 4: Future Outlook - The company is expected to see a profit turning point in 2026 as new capacities are gradually released and innovative product categories accelerate [10]. - The integration of AI and research capabilities is expected to further enhance the company's growth trajectory in the life sciences sector [9].